文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

急性脑损伤中神经肌肉阻滞剂的使用及其与结局的关联:ENIO研究的会后分析

Utilization of Neuromuscular Blocking Agents in Acute Brain Injury and Associations with Outcomes: A Post Hoc Analysis of the ENIO Study.
PubMed 文献 · Neurocrit Care · 2026-03-06
一句话结论急性脑损伤患者中神经肌肉阻滞剂使用率国家间差异大(0%–59.3%),使用与住院死亡率降低(OR 0.35)及机械通气时间延长(OR 1.56)相关。

该研究为多中心前瞻性观察研究(NCT03400904)的会后分析,纳入格拉斯哥昏迷评分≤12分且需要有创机械通气≥24小时的成人急性脑损伤患者。将入住ICU第一周内使用神经肌肉阻滞剂者与未使用者进行倾向性评分匹配,匹配队列258例中33.3%使用神经肌肉阻滞剂,各国使用率0%至59.3%不等。多因素回归显示使用神经肌肉阻滞剂与颅内压监测(OR 2.06)、脑室外引流(OR 2.18)、较高PaCO2(OR 1.04)及中重度急性呼吸窘迫综合征(OR 2.40)相关;使用与住院死亡率降低(OR 0.35)和机械通气时间延长(OR 1.56)相关,与再插管率或气管切开无关联。作者认为这些关联需在随机对照试验中进一步探索。

要点

  • 在匹配队列258例急性脑损伤患者中,33.3%(86例)在入住ICU第一周使用了神经肌肉阻滞剂,各国使用率0%至59.3%。
  • 使用神经肌肉阻滞剂与颅内压监测(OR 2.06,95%CI 1.16-3.76)和脑室外引流(OR 2.18,95%CI 1.18-4.05)相关。
  • 使用神经肌肉阻滞剂与中重度急性呼吸窘迫综合征相关(OR 2.40,95%CI 1.16-5.05),并与较高PaCO2相关(OR 1.04,95%CI 1.01-1.09)。
  • 使用神经肌肉阻滞剂与住院死亡率降低相关(OR 0.35,95%CI 0.11-0.99),与机械通气时间延长相关(OR 1.56,95%CI 1.38-1.76)。
  • 使用神经肌肉阻滞剂与再插管率或气管切开无关联。

适用人群与场景

  • 成人急性脑损伤患者,插管前格拉斯哥昏迷评分≤12分,需要有创机械通气≥24小时。

诊断标准与关键阈值

  • 急性脑损伤定义:插管前格拉斯哥昏迷评分≤12分。

研究设计与关键结果

  • 研究类型:多中心前瞻性观察研究(NCT03400904)的会后分析,采用倾向性评分匹配。
  • 匹配队列共258例,其中33.3%(86例)在入住ICU第一周使用神经肌肉阻滞剂;各国使用率0%至59.3%。
  • 使用神经肌肉阻滞剂与颅内压监测相关(OR 2.06,95%CI 1.16-3.76),与脑室外引流相关(OR 2.18,95%CI 1.18-4.05),与较高PaCO2相关(OR 1.04,95%CI 1.01-1.09),与中重度急性呼吸窘迫综合征相关(OR 2.40,95%CI 1.16-5.05)。
  • 使用神经肌肉阻滞剂与住院死亡率降低相关(OR 0.35,95%CI 0.11-0.99),与机械通气时间延长相关(OR 1.56,95%CI 1.38-1.76);与再插管率或气管切开无关联。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察研究的会后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为神经肌肉阻滞剂使用与结局的关联需在随机对照试验中进一步探索。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Neuromuscular blocking agents (NMBA) have been used in mechanically ventilated patients with moderate-to-severe acute respiratory distress syndrome (ARDS), in cases of clinically significant ventilator dyssynchrony, and in patients with elevated intracranial pressure (ICP). However, practice patterns around NMBA utilization and their impact on outcomes in acute brain injury (ABI) remain insufficiently explored.

METHODS: This study carried out a post hoc analysis of a multicenter, prospective observational study (NCT03400904) including adult patients with ABI (Glasgow Coma Scale ≤ 12 before intubation) who required invasive mechanical ventilation (IMV) ≥ 24 h. Patients who received NMBA during their first week of ICU stay were propensity matched to those who did not.

RESULTS: Propensity score matching was performed in 1482 patients; among the matched cohort (n = 258), 33.3% (n = 86) received NMBA. NMBA utilization varied from 0% to 59.3% across countries. Multivariable regressions demonstrated associations between NMBA use and utilization of intraparenchymal ICP monitoring (odds ratio, OR 2.06; 95% confidence interval, CI 1.16-3.76), extraventricular drain placement (OR 2.18; 95% CI 1.18-4.05), higher PaCO2 values (OR 1.04; 95% CI 1.01-1.09), and moderate-to-severe ARDS (OR 2.40; 95% CI 1.16-5.05). NMBA use was associated with lower hospital mortality (OR 0.35; 95% CI 0.11-0.99) and prolonged IMV duration (OR 1.56; 95% CI 1.38-1.76), but not with reintubation rates or tracheostomy placement.

CONCLUSIONS: NMBA utilization varied widely, highlighting the need for more evidence to guide clinical practice. NMBA were most commonly used in patients with ICP monitoring or moderate-to-severe ARDS; associations with outcomes warrant further exploration in randomized controlled trials.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Berardino A, Gallo F, Battaglini D, et al. Utilization of Neuromuscular Blocking Agents in Acute Brain Injury and Associations with Outcomes: A Post Hoc Analysis of the ENIO Study. Neurocrit Care. 2026. PMID: 41792523. doi:10.1007/s12028-026-02473-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。